MLICM
CASI

Metropolitan Life Insurance Company (MetLife)’s CASI Pharmaceuticals CASI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1,895
Closed -$76.2K – 2554
2018
Q4 		$76.2K Buy
1,895
+36
+2% +$1.36K ﹤0.01% 2447
2018
Q3 		$86.8K Hold
1,859
– – ﹤0.01% 2509
2018
Q2 		$153K Buy
+1,859
New +$125K ﹤0.01% 2103

Other funds holding CASI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CASI Position: Q1 2019 in Review

Metropolitan Life Insurance Company (MetLife) sold out of CASI Pharmaceuticals (CASI) in Q1 2019, closing a stake of 1,895 shares — an estimated $76.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CASI in Q2 2018 and held it in 3 quarters. The position peaked at $153K in Q2 2018. 52 funds tracked by Wall St. Rank hold CASI as of Q1 2019.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining CASI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,895 CASI Pharmaceuticals shares in Q1 2019, an estimated $76.2K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in CASI Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s CASI Pharmaceuticals position peaked at $153K in Q2 2018.
  • 52 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q1 2019.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2019, filed 15 May 2019.